金城医药：本次在合并报表范围内计提资产减值准备共计5566.24万元

Group 1 - The company Jin Cheng Pharmaceutical announced on January 30 that it has recognized an asset impairment provision totaling 55.6624 million yuan, which will be included in the company's 2025 financial results [1] - This impairment is expected to reduce the net profit attributable to shareholders of the listed company by approximately 49.6106 million yuan for the year 2025 [1] - The total equity attributable to shareholders of the listed company will also decrease by about 49.6106 million yuan [1] Group 2 - The nuclear power construction industry is experiencing a surge, with equipment manufacturers reportedly busy with orders scheduled until 2028 [1] - Employees are working in three shifts, and production lines are operating 24 hours a day to meet the high demand [1]